GlassScriptPhysician profile
Juan P Aponte
NPI 1376526947
$9,648.89
in general payments reported to CMS, 2019-2025
34 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,353 · 2020: $2,567 · 2021: $1,320 · 2022: $1,014 · 2023: $1,086 · 2024: $739 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.75 |
| Education | $122.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,457.12 | 2019-2025 | |
| Novo Nordisk INC | $1,767.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $697.31 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Abbott Laboratories | $598.12 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $426.32 | 2019-2023 | Myrbetriq, Veozah |
| Esperion Therapeutics, INC. | $260.50 | 2020-2021 | |
| Lilly USA, LLC | $204.36 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Dexcom, INC. | $132.42 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $113.94 | 2023-2024 | Gvoke Hypopen |
| Insightec,INC | $110.83 | 2024 | Exablate |
| Janssen Pharmaceuticals, INC | $105.95 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $81.87 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $65.43 | 2020-2021 | |
| Amarin Pharma, INC. | $62.70 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.03 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $53.71 | 2023-2024 | Vyepti |
| Sunovion Pharmaceuticals INC. | $51.71 | 2019 | |
| Neurocrine Biosciences, INC. | $47.76 | 2022 | |
| Amgen INC. | $45.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $37.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.77 | 2024-2025 | Xifaxan |
| Shield Therapeutics INC | $25.90 | 2025 | |
| Allergan, INC. | $25.75 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $25.44 | 2021-2022 | |
| Biogen, INC. | $21.50 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.73 | 2022 | |
| Sk Life Science, INC. | $17.77 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.53 | 2024 | Voquezna |
| Ani Pharmaceuticals, INC. | $16.97 | 2025 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $16.32 | 2025 | Inspire |
| Kyowa Kirin, INC. | $14.53 | 2025 | |
| Glaxosmithkline, LLC. | $13.82 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.18 | 2021 | |
| Dynavax Technologies Corporation | $3.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Aponte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.